CX3CR1 and glioma: Cross-disease evidence—including systemic inflammatory disorders [206], low-grade gliomas (LGGs) [207], subarachnoid hemorrhage (SAH) [208], and aortic aneurysms (AAs) [40])—has elucidated the clinical translational potential of CX3CR1 through single-cell transcriptomics, genome-wide association studies (GWAS), or postmortem tissue analyses; however, direct clinical evidence defining optimal therapeutic time windows for CX3CR1-targeted interventions in ischemic stroke remains limited.